IMARC opens new office in Minnesota

IMARC Research, a CRO based in Strongsville, OH, is opening a new office in the Minneapolis area in an effort to gain a bigger share of the medical device market.

The Minneapolis area is home to many medical device companies: One of the moguls, Medtronic, for example, was founded in northeast Minneapolis; though it has moved its company headquarters to Ireland, it still has operational headquarters in Minneapolis, MN. St. Jude Medical and Boston Scientific are also among the big medical device companies located in the state.

“[T]his new location will allow us to better serve our current clients and develop exciting new partnerships," IMARC CEO and President Sandra Maddock said in a statement about the new branch.

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

The 17-year-old CRO currently offers services across the span of clinical research assistance, from training staff and site support all the way to auditing and project management, among others. Having worked at over 100 sites, IMARC has never received an FDA warning letter, said John Lehmann, the company’s director of business development.

The new office will be set up in Minnetonka, MN, and led by the company’s senior clinical research specialist James Moat, who has more than 26 years of experience in medical device product development.

The company is not separating functions between the two offices, but will provide the same services in both, said Lehmann. Three employers are currently based in the new location and the company plans to hire additional staff soon.

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.